Aveo planning tivozanib MAA

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rose $0.17 to $2.49 on Thursday after it released details of its pre-MAA meeting with EMA's CHMP for tivozanib to treat renal cell carcinoma (RCC). The company said a rapporteur and co-rapporteur from the committee would support submission of an MAA using data from the Phase III TIVO-1 study of the candidate as first-line treatment of RCC.

Aveo President and CEO Michael Bailey told BioCentury that Aveo hopes to submit an MAA to EMA in first-line RCC by YE15. ...